New drug targets for type 2 diabetes and the metabolic syndrome

David E. Moller(Merck & Co., Inc., Rahway, NJ, USA (United States))

Nature

December 1, 2001

10.1038/414821a

Cited by 1,009

Abstract

Related Papers

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

Toshimasa Yamauchi, Junji Kamon, Hironori Waki et al.|Nature Medicine|2001|4.9k

The hormone resistin links obesity to diabetes

Claire M. Steppan, Shannon T. Bailey, Savitha Bhat et al.|Nature|2001|4.8k

Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice

Dennis Huszar, Catherine Lynch, Victoria Fairchild-Huntress et al.|Cell|1997|3k

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

Anders H. Berg, Terry P. Combs, Xueliang Du et al.|Nature Medicine|2001|2.5k

The PPARs: From Orphan Receptors to Drug Discovery

Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach et al.|Journal of Medicinal Chemistry|2000|1.8k